Railways approves Rs 499 Crore Mansi-Saharsa Doubling Project (See 'Corp Brief') Five New Sub-Regional Offices of ESIC to be set up across India (See 'Corp Brief') Govt extends full customs duty exemption on critical petrochemical products (See 'Corp Brief') Contempt of Court - Contempt jurisdiction cannot be invoked based on expansive or alternative interpretation of Court's orders - only clear, explicit & willful disobedience can be penalised: HC (See 'Legal Desk') CEA organizes All-India Electrical Safety awareness programme (See 'Corp Brief') Regional industries must become partners in Viksit Bharat journey: RM (See 'Corp Brief') Union Minister reviews MSME Schemes in Ladakh (See 'Corp Brief') Competition Act - Allegation pertaining to a service dispute between a user & a platform service provider w.r.t. subscription management, cancellation of service & compensation, does not come under ambit of Section 4 of the Act: CCI (See 'Legal Desk') MPEDA to organise Second National Seafood Skill Olympiad during Seafood Expo Bharat 2026 (See 'Corp Brief') India's Space and Biotechnology Sectors present new collaboration opportunities: MoS (See 'Corp Brief') IPR - After pronouncement of final judgment and decree under Order XX CPC, Court becomes functus officio and cannot grant liberty for post-decree impleadment of mirror/redirect/alphanumeric websites: HC (See 'Legal Desk') Office of Principal Scientific Adviser signs MoU with Data Security Council of India (See 'Corp Brief') Telangana strengthens Clean Cities Through Behaviour Change and Citizen Action (See 'Corp Brief') IPR - If essential and dominant feature of earlier mark is fully contained in later mark, and later mark is only pluralized form that conveys same meaning, later mark can be held deceptively similar: HC (See 'Legal Desk') JP Nadda To Release Guidelines For 'Anaemia Mukt Bharat Abhiyaan' Today (See 'Corp Brief') A&C - Restraint on alienation of assets cannot be imposed when such relief was neither specifically sought nor argued in Section 17 application: HC (See 'Legal Desk') Environment Minister inaugurates workshop on tiger reintroduction in Sariska (See 'Corp Brief') JP Nadda to unveil healthcare programme for children up to three years (See 'Corp Brief') A&C - Scope of scrutiny u/s 11 is confined to prima facie examination of existence of arbitration agreement & does not extend to adjudication of disputed questions of fact or law: HC (See 'Legal Desk') Dasheri, Chausa, Langra and Kesar showcase Rich Diversity of Indian Mangoes (See 'Corp Brief') FEMA - Statutory protection under Section 6(4) cannot be invoked to legitimise unexplained or inadequately accounted foreign exchange transactions: SAFEMA (See 'Legal Desk') Ease of Doing Business: Irritants eased out of FSSAI Licensing Regulations (See 'Corp Brief') SEBI - Failure to file Quarterly Activity Reports for multiple consecutive quarters constitutes violation of regulatory framework & attracts consequences prescribed under Regulation 35 of AIF Regulations, 2012: SEBI (See 'Legal Desk') AI, Nuclear, Space, Quantum tech to determine contours of future growth: MoS (See 'Corp Brief') SARFAESI - In absence of any adjudication by the DRT in determining the debt, statutory scheme permits reliance upon claim made by secured creditor for purpose of fixing pre-deposit: HC (See 'Legal Desk') Tech Innovation and disruption in Construction Industry (See 'CORP EINSICHT')

Print

Govt issues updated management protocol for managing COVID-19 cases

Published: Jun 27, 2020

By TIOLCORPLAW News Service

NEW DELHI, JUNE 27, 2020: Keeping pace with evolving knowledge about COVID-19, especially in terms of effective drugs, the Union Ministry of Health & Family Welfare has today released an updated clinical management protocol for managing COVID-19 cases. The updated protocol includes the advice to use Dexamethasone as an alternative choice to Methylprednisolone for managing moderate to severe cases of COVID-19. The change has been made after considering the latest available evidence and expert consultation.

Dexamethasone is a corticosteroid drug used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects. The drug has been tested in hospitalized patients with COVID-19 in the RECOVERY clinical trial and was found to have benefits for critically ill patients and has been shown to reduce mortality by about one third for patients on ventilators, and by about one fifth for patients being maintained on oxygen therapy. The drug is also a part of the National List of Essential Medicines (NLEM) and is widely available.

The Union Health Secretary, Ms Preeti Sudan, has forwarded the updated protocol with all States/UTs to make necessary arrangements for availability and use of the updated protocol and drug Dexamethasone at the institutional level also. The guidance document has also been made available online on the website of the Health Ministry at:

https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19dated27062020.pdf

The last update to the clinical management protocol was done on 13th June, 2020.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.